

Supplemental Tables for:  
Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers  
Walid Shaib et al.

**Supplemental Table S1:** Genes sequenced by Guardant360 and all four major classes of alterations

<b>Point Mutations (SNVs)</b> <b>(73 Genes)</b>	<b>Indels</b> <b>(23 Genes)</b>	<b>Amplifications</b> <b>(18 Genes)</b>	<b>Fusions</b> <b>(6 Genes)</b>
<i>AKT1</i> <i>SMO</i> <i>ARAF</i>	<i>ATM</i>	<i>AR</i>	<i>ALK</i>
<i>ATM</i> <i>APC</i> <i>CCND1</i>	<i>ARID1A</i>	<i>CCND1</i>	<i>FGFR2</i>
<i>CCNE1</i> <i>BRCA1</i> <i>CDKN2A</i>	<i>BRCA2</i>	<i>CCNE1</i>	<i>FGFR3</i>
<i>DDR2</i> <i>CDK4</i> <i>EZH2</i>	<i>CDKN2A</i>	<i>CDK6</i>	<i>NTRK1</i>
<i>FGFR1</i> <i>ERBB2 (HER2)</i> <i>GNA11</i>	<i>ERBB2</i>	<i>ERBB2</i>	<i>RET</i>
<i>GNAS</i> <i>FGFR3</i> <i>IDH2</i>	<i>KIT</i>	<i>FGFR2</i>	<i>ROS1</i>
<i>JAK3</i> <i>HRAS</i> <i>MAP2K2/MEK2</i>	<i>MLH1</i>	<i>KRAS</i>	
<i>MAPK3/ERK1</i> <i>KRAS</i> <i>MTOR</i>	<i>NF1</i>	<i>MYC</i>	
<i>NF1</i> <i>MLH1</i> <i>NRAS</i>	<i>PTEN</i>	<i>PIK3CA</i>	
<i>RB1</i> <i>NOTCH1</i> <i>PTPN11</i>	<i>SMAD4</i>	<i>BRAF</i>	
<i>SMAD4</i> <i>PIK3CA</i> <i>RIT1</i>	<i>TP53</i>	<i>CCND2</i>	
<i>VHL</i> <i>RHEB</i> <i>TP53</i>	<i>VHL</i>	<i>CDK4</i>	
<i>ALK</i> <i>STK11</i> <i>ARID1A</i>	<i>APC</i>	<i>EGFR</i>	
<i>BRAF</i> <i>AR</i> <i>CCND2</i>	<i>BRCA1</i>	<i>FGFR1</i>	
<i>CDH1</i> <i>BRCA2</i> <i>CTNNB1</i>	<i>CDH1</i>	<i>KIT</i>	
<i>EGFR</i> <i>CDK6</i> <i>FBXW7</i>	<i>EGFR</i>	<i>MET</i>	
<i>FGFR2</i> <i>ESR1</i> <i>GNAQ</i>	<i>GATA3</i>	<i>PDGFRA</i>	
<i>HNF1A</i> <i>GATA3</i> <i>JAK2</i>	<i>MET</i>	<i>RAF1</i>	
<i>KIT</i> <i>IDH1</i> <i>MAPK1/ERK2</i>	<i>MTOR</i>		
<i>MET</i> <i>MAP2K1/MEK1</i> <i>MYC</i>	<i>PDGFRA</i>		
<i>NFE2L2</i> <i>MPL</i> <i>NTRK1</i>	<i>RB1</i>		
<i>PDGFRA</i> <i>NPM1</i> <i>RAF1</i>	<i>STK11</i>		
<i>RET</i> <i>RHOA</i> <i>ROS1</i>	<i>TSC1</i>		
<i>PTEN</i> <i>TERT</i> <i>SC1</i>			
<i>NTRK3</i>			

**Supplemental Table S2:** Correlation between age and gender with respect to KRAS/BRAF/ATM/BRCA

<b>Gene</b>	<b>Count of Gene</b>	<b>Male</b>	<b>Female</b>	<b>Mean Age (Years)</b>
<i>KRAS</i>	41	21/41 (51%)	20/41 (49%)	53.5
<i>BRAF</i>	13	7/13 (54%)	6/13 (46%)	58.9
<i>ATM</i>	6	3/6 (50%)	3/6 (50%)	51.7
<i>BRCA 1</i>	1	0/1 (0%)	1/1 (100%)	51
<i>BRCA 2</i>	1	0/1 (0%)	1/1 (100%)	60